SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Human Genome Sciences, Inc. (HGSI)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Vector1 who wrote (68)3/2/1997 2:50:00 AM
From: Troll_29   of 1127
 
Vector:

I understand the Clinton Administration cut or eliminated funding for 550 patent reviewer positions. Last year the number of patents that could be filed with a single application was severely restricted while the fee to file was either held constant or increased. Do you know if I am wrong? If this is correct, wouldn't it increase the potential value of pending applications that have been filed and/or granted. Wouldn't this be a consideration that likely has not been factored into HGSI's stock price -- there was no increase in stock price when the news media reported that the changes took effect. Given the lead time to develop marketable products, isn't the duration of HGSI's research also a positive factor? I am asking because of your assertion that you are a professional investor and you seem to know something about HGSI.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News